Pub Date : 2025-02-01DOI: 10.1016/j.jncc.2024.05.006
Giorgio Broccia , Jonathan Carter , Cansu Ozsin-Ozler , Sara De Matteis , Pierluigi Cocco
Background
The epidemiological investigation of Hodgkin's lymphoma (HL) among the genetically peculiar population of the Italian island of Sardinia might provide interesting etiological clues.
Methods
We used the database of 1974–2003 incident cases of hematological malignancies in Sardinia and Bayesian methods to explore the time trend and geographic spread of HL incidence by sex, and age whether ≤44 or ≥45 years. We also tested its association with several socio-economic and environmental risk factors.
Results
The age- and sex-standardized (world population) incidence rate of HL was 2.6 per 100,000 (95% CI, 2.5–2.8). Over the study period, HL incidence increased linearly in both sexes and among those aged ≤44 years but not above that age. Cases clustered among young women in a central-western area covering four bordering administrative units (13 cases vs. 5.7 expected, P = 0.002). The posterior probability of excess HL cases aged ≤44 years was elevated only in a commune in the suburban area of the region's capital. Cases aged ≥45 years were uniformly spread over the region. Among the risk factors we explored, urban residence was associated with an elevated and goat farming with a decreased risk of HL occurrence. We did not observe a link with socio-economic deprivation, environmental exposures, or multiple sclerosis. The geographic spread of COVID-19 was also unrelated to past HL incidence.
Conclusions
Our results prompt further in-depth investigation into the previously undetected cluster and the nature of the observed associations.
{"title":"Time and space co-ordinates of Hodgkin's lymphoma in Sardinia, Italy","authors":"Giorgio Broccia , Jonathan Carter , Cansu Ozsin-Ozler , Sara De Matteis , Pierluigi Cocco","doi":"10.1016/j.jncc.2024.05.006","DOIUrl":"10.1016/j.jncc.2024.05.006","url":null,"abstract":"<div><h3>Background</h3><div>The epidemiological investigation of Hodgkin's lymphoma (HL) among the genetically peculiar population of the Italian island of Sardinia might provide interesting etiological clues.</div></div><div><h3>Methods</h3><div>We used the database of 1974–2003 incident cases of hematological malignancies in Sardinia and Bayesian methods to explore the time trend and geographic spread of HL incidence by sex, and age whether ≤44 or ≥45 years. We also tested its association with several socio-economic and environmental risk factors.</div></div><div><h3>Results</h3><div>The age- and sex-standardized (world population) incidence rate of HL was 2.6 per 100,000 (95% CI, 2.5–2.8). Over the study period, HL incidence increased linearly in both sexes and among those aged ≤44 years but not above that age<em>.</em> Cases clustered among young women in a central-western area covering four bordering administrative units (13 cases <em>vs.</em> 5.7 expected, <em>P</em> = 0.002). The posterior probability of excess HL cases aged ≤44 years was elevated only in a commune in the suburban area of the region's capital. Cases aged ≥45 years were uniformly spread over the region. Among the risk factors we explored, urban residence was associated with an elevated and goat farming with a decreased risk of HL occurrence. We did not observe a link with socio-economic deprivation, environmental exposures, or multiple sclerosis. The geographic spread of COVID-19 was also unrelated to past HL incidence.</div></div><div><h3>Conclusions</h3><div>Our results prompt further in-depth investigation into the previously undetected cluster and the nature of the observed associations.</div></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"5 1","pages":"Pages 50-56"},"PeriodicalIF":7.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143386577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.jncc.2024.10.001
Xiaojie Liang , Jia Guo , Xiaofang Wang , Baiwei Luo , Ruiying Fu , Haiying Chen , Yunong Yang , Zhihao Jin , Chaoran Lin , Aimin Zang , Youchao Jia , Lin Feng , Liang Wang
Background
Previous researches mainly focused on whether cancer stem cells exist in diffuse large B-cell lymphoma (DLBCL). However, subgroups with dismal prognosis and stem cell-like characteristics have been overlooked.
Methods
Using large scale data (n = 2133), we conducted machine learning algorithms to identify a high risk DLBCL subgroup with stem cell-like features, and then investigated the potential mechanisms in shaping this subgroup using transcriptome, genome and single-cell RNA-seq data, and in vitro experiments.
Results
We identified a high-risk subgroup (25.6 % of DLBCL) with stem cell-like characteristics and dismal prognosis. This high-risk group (HRG) was featured by upregulation of key enzyme (ODC1) in polyamine metabolism and cold tumor microenvironment (TME), and had a poor prognosis with lower 3-year overall survival (OS) (54.3 % vs. 83.6 %, P < 0.0001) and progression-free survival (PFS) (42.8 % vs. 74.7 %, P < 0.0001) rates compared to the low-risk group. HRG also exhibited malignant proliferative phenotypes similar to Burkitt lymphoma. Patients with MYC rearrangement, double-hit, double-expressors, or complete remission might have either favorable or poor prognosis, which could be further distinguished by our risk stratification model. Genomic analysis revealed widespread copy number losses in the chemokine and interferon coding regions 8p23.1 and 9p21.3 in HRG. We identified ODC1 as a therapeutic vulnerability for HRG-DLBCL. Single-cell analysis and in vitro experiments demonstrated that ODC1 overexpression enhanced DLBCL cell proliferation and drove macrophage polarization towards the M2 phenotype. Conversely, ODC1 inhibition reduced DLBCL cell proliferation, induced cell cycle arrest and apoptosis, and promoted macrophage polarization towards the M1 phenotype. Finally, we developed a comprehensive database of DLBCL for clinical application.
Conclusions
Our study effectively advances the precise risk stratification of DLBCL and reveals that ODC1 and immune-deserted microenvironment jointly shape a group of DLBCL patients with stem cell-like features. Targeting ODC1 regulates immunotherapies in DLBCL, offering new insights for DLBCL treatment.
背景以往的研究主要集中在弥漫性大b细胞淋巴瘤（DLBCL）中是否存在肿瘤干细胞。然而，预后不良和干细胞样特征的亚群被忽视了。方法利用大规模数据（n = 2133），采用机器学习算法识别具有干细胞样特征的高危DLBCL亚群，然后利用转录组、基因组和单细胞RNA-seq数据以及体外实验研究塑造该亚群的潜在机制。结果我们确定了一个高风险亚组（占DLBCL的25.6 %），具有干细胞样特征，预后不佳。该高危组（HRG）多胺代谢关键酶（ODC1）和冷肿瘤微环境（TME）上调，预后较差，3年总生存率（OS）较低(54.3% % vs. 83.6 %,P <；0.0001)和无进展生存期（PFS）(42.8 % vs. 74.7 %,P <；0.0001)，与低风险组相比。HRG也表现出与伯基特淋巴瘤相似的恶性增生性表型。MYC重排、双击中、双表达或完全缓解的患者可能有良好或不良的预后，这可以通过我们的风险分层模型进一步区分。基因组分析显示，HRG中趋化因子和干扰素编码区8p23.1和9p21.3拷贝数普遍缺失。我们确定ODC1是HRG-DLBCL的治疗易损。单细胞分析和体外实验表明，ODC1过表达增强DLBCL细胞增殖，驱动巨噬细胞向M2表型极化。相反，ODC1抑制降低DLBCL细胞增殖，诱导细胞周期阻滞和凋亡，促进巨噬细胞向M1表型极化。最后，我们建立了一个完整的DLBCL数据库以供临床应用。结论我们的研究有效地推进了DLBCL的精确风险分层，揭示了ODC1和免疫遗弃微环境共同塑造了一组具有干细胞样特征的DLBCL患者。靶向ODC1调节DLBCL的免疫治疗，为DLBCL治疗提供新的见解。
{"title":"Overexpression of ornithine decarboxylase 1 mediates the immune-deserted microenvironment and poor prognosis in diffuse large B-cell lymphoma","authors":"Xiaojie Liang , Jia Guo , Xiaofang Wang , Baiwei Luo , Ruiying Fu , Haiying Chen , Yunong Yang , Zhihao Jin , Chaoran Lin , Aimin Zang , Youchao Jia , Lin Feng , Liang Wang","doi":"10.1016/j.jncc.2024.10.001","DOIUrl":"10.1016/j.jncc.2024.10.001","url":null,"abstract":"<div><h3>Background</h3><div>Previous researches mainly focused on whether cancer stem cells exist in diffuse large B-cell lymphoma (DLBCL). However, subgroups with dismal prognosis and stem cell-like characteristics have been overlooked.</div></div><div><h3>Methods</h3><div>Using large scale data (<em>n</em> = 2133), we conducted machine learning algorithms to identify a high risk DLBCL subgroup with stem cell-like features, and then investigated the potential mechanisms in shaping this subgroup using transcriptome, genome and single-cell RNA-seq data, and <em>in vitro</em> experiments.</div></div><div><h3>Results</h3><div>We identified a high-risk subgroup (25.6 % of DLBCL) with stem cell-like characteristics and dismal prognosis. This high-risk group (HRG) was featured by upregulation of key enzyme (ODC1) in polyamine metabolism and cold tumor microenvironment (TME), and had a poor prognosis with lower 3-year overall survival (OS) (54.3 % vs. 83.6 %, <em>P</em> < 0.0001) and progression-free survival (PFS) (42.8 % vs. 74.7 %, <em>P</em> < 0.0001) rates compared to the low-risk group. HRG also exhibited malignant proliferative phenotypes similar to Burkitt lymphoma. Patients with <em>MYC</em> rearrangement, double-hit, double-expressors, or complete remission might have either favorable or poor prognosis, which could be further distinguished by our risk stratification model. Genomic analysis revealed widespread copy number losses in the chemokine and interferon coding regions 8p23.1 and 9p21.3 in HRG. We identified ODC1 as a therapeutic vulnerability for HRG-DLBCL. Single-cell analysis and <em>in vitro</em> experiments demonstrated that ODC1 overexpression enhanced DLBCL cell proliferation and drove macrophage polarization towards the M2 phenotype. Conversely, ODC1 inhibition reduced DLBCL cell proliferation, induced cell cycle arrest and apoptosis, and promoted macrophage polarization towards the M1 phenotype. Finally, we developed a comprehensive database of DLBCL for clinical application.</div></div><div><h3>Conclusions</h3><div>Our study effectively advances the precise risk stratification of DLBCL and reveals that ODC1 and immune-deserted microenvironment jointly shape a group of DLBCL patients with stem cell-like features. Targeting ODC1 regulates immunotherapies in DLBCL, offering new insights for DLBCL treatment.</div></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"5 1","pages":"Pages 57-74"},"PeriodicalIF":7.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143386579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.jncc.2024.12.005
Lanlan Pang , Weitao Zhuang , Yihua Huang, Jun Liao, Mengjuan Yang, Li Zhang, Yaxiong Zhang, Wenfeng Fang
Background
Phenotypic transition is a common resistance mechanism of targeted therapy. While transformations from lung adenocarcinoma (LUAD) to small-cell lung cancer or squamous-cell carcinoma have been extensively studied, the conversion into sarcomatoid carcinoma (SC) is rarely reported.
Methods
Genetic and histological examinations were systematically performed on tumor re-biopsy samples obtained from patients with advanced EGFR-mutant LUAD who progressed on EGFR-tyrosine kinase inhibitors (TKIs). EGFR wild-type patients were also identified who underwent the rare transformation from adenocarcinoma to SC following the ineffectiveness of inhibitors that target distinct driver oncogenes. Furthermore, we also retrospectively collected 42 cases diagnosed with primary pulmonary SC as a comparison cohort to comprehensively characterize the biological events and clinical outcomes of transformed SC.
Results
The sarcomatoid transformation mediated drug resistance in 2.5 % and 4.8 % of patients after failure on the first/second, and third-generation EGFR-TKIs. Transformation of sarcomatoid carcinoma is characterized by a higher frequency of TP53, RB1, and MET genetic alterations compared to cases lacking histological transformation; the PI3K signaling pathway was also significantly activated. Fifteen individuals were identified with a rare transition from adenocarcinoma to SC, consisting of seven cases with EGFR-activating mutations and eight cases without EGFR mutations. All sarcomatoid-transformed samples not only retained their original driver mutations but also shared specific genetic alterations with primary LUAD. Moreover, transformed sarcomatoid carcinomas mimic the primary SC in terms of immunochemical and molecular features.
Conclusions
The transformation from lung adenocarcinoma to SC is a resistance mechanism wildly applied to inhibitors targeting different driver oncogenes. Immunotherapy plus chemotherapy shows potential to benefit patients with sarcomatoid transformation and warrants further study in larger cohorts.
{"title":"Rare transformation from lung adenocarcinoma to sarcomatoid carcinoma mediates resistance to inhibitors targeting different driver oncogenes","authors":"Lanlan Pang , Weitao Zhuang , Yihua Huang, Jun Liao, Mengjuan Yang, Li Zhang, Yaxiong Zhang, Wenfeng Fang","doi":"10.1016/j.jncc.2024.12.005","DOIUrl":"10.1016/j.jncc.2024.12.005","url":null,"abstract":"<div><h3>Background</h3><div>Phenotypic transition is a common resistance mechanism of targeted therapy. While transformations from lung adenocarcinoma (LUAD) to small-cell lung cancer or squamous-cell carcinoma have been extensively studied, the conversion into sarcomatoid carcinoma (SC) is rarely reported.</div></div><div><h3>Methods</h3><div>Genetic and histological examinations were systematically performed on tumor re-biopsy samples obtained from patients with advanced EGFR-mutant LUAD who progressed on EGFR-tyrosine kinase inhibitors (TKIs). EGFR wild-type patients were also identified who underwent the rare transformation from adenocarcinoma to SC following the ineffectiveness of inhibitors that target distinct driver oncogenes. Furthermore, we also retrospectively collected 42 cases diagnosed with primary pulmonary SC as a comparison cohort to comprehensively characterize the biological events and clinical outcomes of transformed SC.</div></div><div><h3>Results</h3><div>The sarcomatoid transformation mediated drug resistance in 2.5 % and 4.8 % of patients after failure on the first/second, and third-generation EGFR-TKIs. Transformation of sarcomatoid carcinoma is characterized by a higher frequency of <em>TP53, RB1</em>, and <em>MET</em> genetic alterations compared to cases lacking histological transformation; the PI3K signaling pathway was also significantly activated. Fifteen individuals were identified with a rare transition from adenocarcinoma to SC, consisting of seven cases with <em>EGFR</em>-activating mutations and eight cases without <em>EGFR</em> mutations. All sarcomatoid-transformed samples not only retained their original driver mutations but also shared specific genetic alterations with primary LUAD. Moreover, transformed sarcomatoid carcinomas mimic the primary SC in terms of immunochemical and molecular features.</div></div><div><h3>Conclusions</h3><div>The transformation from lung adenocarcinoma to SC is a resistance mechanism wildly applied to inhibitors targeting different driver oncogenes. Immunotherapy plus chemotherapy shows potential to benefit patients with sarcomatoid transformation and warrants further study in larger cohorts.</div></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"5 1","pages":"Pages 75-81"},"PeriodicalIF":7.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143386580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01DOI: 10.1016/j.jncc.2024.07.001
Yuechao Yang , Huanhuan Cui , Deheng Li , Lei Chen , Yi Liu , Changshuai Zhou , Liangdong Li , Mingtao Feng , Xin Chen , Yiqun Cao , Yang Gao
Background
S100A8 is a member of the S100 protein family and plays a pivotal role in regulating inflammation and tumor progression. This study aimed to comprehensively assess the expression patterns and functional roles of S100A8 in glioma progression.
Methods
Glioma tissues were collected from 98 patients who underwent surgical treatment at Fudan University Shanghai Cancer Center. S100A8 expression in glioma tissues was analyzed using immunohistochemistry (IHC) to establish its correlation with clinicopathological features in patients. The expression and prognostic effect of S100A8 in glioma were analyzed using TCGA and CGGA public databases. Then, we investigated the role of S100A8 in glioma through a series of in vivo and in vitro experiments including Transwell, wound healing, CCK8, and intracranial tumor models. Subsequently, bioinformatics analysis, single-cell sequencing and coimmunoprecipitation (Co-IP) were used to explore the underlying mechanism.
Results
S100A8 was upregulated in gliomas compared to paracancerous tissues, and this phenotype was significantly correlated with poor prognosis. Subgroup analysis showed that S100A8 expression was higher in the high-grade glioma (HGG) group than that in the low-grade glioma (LGG) group. S100A8 overexpression in glioma cell lines promoted cell proliferation, migration and invasion, while silencing S100A8 reversed these effects. In vivo experiments showed that S100A8 knockdown can significantly reduce the tumor burden of glioma cells. Notably, S100A8 was observed to stimulate microglial M2 polarization by interacting with TLR4, which subsequently induced NF-κB signaling and IL-10 secretion within the tumor microenvironment.
Conclusions
S100A8 promotes tumor progression by inducing phenotypic polarization of microglia through the TLR4/IL-10 signaling pathway in glioma. It might represent a therapeutic target for further basic research or clinical management of glioma.
{"title":"S100A8 promotes tumor progression by inducing phenotypic polarization of microglia through the TLR4/IL-10 signaling pathway in glioma","authors":"Yuechao Yang , Huanhuan Cui , Deheng Li , Lei Chen , Yi Liu , Changshuai Zhou , Liangdong Li , Mingtao Feng , Xin Chen , Yiqun Cao , Yang Gao","doi":"10.1016/j.jncc.2024.07.001","DOIUrl":"10.1016/j.jncc.2024.07.001","url":null,"abstract":"<div><h3>Background</h3><div>S100A8 is a member of the S100 protein family and plays a pivotal role in regulating inflammation and tumor progression. This study aimed to comprehensively assess the expression patterns and functional roles of S100A8 in glioma progression.</div></div><div><h3>Methods</h3><div>Glioma tissues were collected from 98 patients who underwent surgical treatment at Fudan University Shanghai Cancer Center. S100A8 expression in glioma tissues was analyzed using immunohistochemistry (IHC) to establish its correlation with clinicopathological features in patients. The expression and prognostic effect of S100A8 in glioma were analyzed using TCGA and CGGA public databases. Then, we investigated the role of S100A8 in glioma through a series of <em>in vivo</em> and <em>in vitro</em> experiments including Transwell, wound healing, CCK8, and intracranial tumor models. Subsequently, bioinformatics analysis, single-cell sequencing and coimmunoprecipitation (Co-IP) were used to explore the underlying mechanism.</div></div><div><h3>Results</h3><div>S100A8 was upregulated in gliomas compared to paracancerous tissues, and this phenotype was significantly correlated with poor prognosis. Subgroup analysis showed that S100A8 expression was higher in the high-grade glioma (HGG) group than that in the low-grade glioma (LGG) group. S100A8 overexpression in glioma cell lines promoted cell proliferation, migration and invasion, while silencing S100A8 reversed these effects. <em>In vivo</em> experiments showed that S100A8 knockdown can significantly reduce the tumor burden of glioma cells. Notably, S100A8 was observed to stimulate microglial M2 polarization by interacting with TLR4, which subsequently induced NF-κB signaling and IL-10 secretion within the tumor microenvironment.</div></div><div><h3>Conclusions</h3><div>S100A8 promotes tumor progression by inducing phenotypic polarization of microglia through the TLR4/IL-10 signaling pathway in glioma. It might represent a therapeutic target for further basic research or clinical management of glioma.</div></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"4 4","pages":"Pages 369-381"},"PeriodicalIF":7.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141844118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01DOI: 10.1016/j.jncc.2024.06.001
Aihetaimujiang Anwaier , Xiangxian Che , Lei Shi , Xi Tian , Shiqi Ye , Wenhao Xu , Yu Zhu , Hailiang Zhang , Dingwei Ye
Background
Completely endophytic renal tumors (CERT) pose significant challenges due to their anatomical complexity and loss of visual clues about tumor location. A facile scoring model based on three-dimensional (3D) reconstructed images will assist in better assessing tumor location and vascular variations.
Methods
In this retrospective study, 80 patients diagnosed with CERT were included. Forty cases underwent preoperative assessment using 3D reconstructed imaging (3D-Cohort), while the remaining 40 cases were assessed using two-dimensional imaging (2D-Cohort). Vascular variations were evaluated by ascertaining the presence of renal arteries > 1, prehilar branching arteries, and arteries anterior to veins. The proposed scoring system, termed RAL, encompassed three critical components: (R)adius (maximal tumor diameter in cm), (A)rtery (occurrence of arterial variations), and (L)ocation relative to the polar line. Comparison of the RAL scoring system was made with established nephrometry scoring systems.
Results
A total of 48 (60%) patients exhibited at least one vascular variation. In the 2D-Cohort, patients with vascular variations experienced significantly prolonged operation time, increased bleeding volume, and extended warm ischemia time compared with those without vascular variations. Conversely, the presence of vascular variations did not significantly affect operative parameters in the 3D-Cohort. Furthermore, the 2D-Cohort demonstrated a notable decline in both short- and long-term estimated glomerular filtration rate (eGFR) changes compared with the 3D-Cohort, a trend consistent across patients with warm ischemia time ≥ 25 min and those with vascular variations. Notably, the 2D-Cohort exhibited a larger margin of normal renal tissue compared with the 3D-Cohort. Elevated RAL scores correlated with larger tumor size, prolonged operation time, extended warm ischemia time, and substantial postoperative eGFR decrease. The RAL scoring system displayed superior predictive capabilities in assessing postoperative eGFR changes compared with conventional nephrometry scoring systems.
Conclusions
Our proposed 3D vascular variation-based nephrometry scoring system offers heightened proficiency in preoperative assessment, precise prediction of surgical complexity, and more accurate evaluation of postoperative renal function in CERT patients.
{"title":"Construction and application of a three-dimensional vascular variation-based nephrometry scoring system for completely endophytic renal tumors","authors":"Aihetaimujiang Anwaier , Xiangxian Che , Lei Shi , Xi Tian , Shiqi Ye , Wenhao Xu , Yu Zhu , Hailiang Zhang , Dingwei Ye","doi":"10.1016/j.jncc.2024.06.001","DOIUrl":"10.1016/j.jncc.2024.06.001","url":null,"abstract":"<div><h3>Background</h3><div>Completely endophytic renal tumors (CERT) pose significant challenges due to their anatomical complexity and loss of visual clues about tumor location. A facile scoring model based on three-dimensional (3D) reconstructed images will assist in better assessing tumor location and vascular variations.</div></div><div><h3>Methods</h3><div>In this retrospective study, 80 patients diagnosed with CERT were included. Forty cases underwent preoperative assessment using 3D reconstructed imaging (3D-Cohort), while the remaining 40 cases were assessed using two-dimensional imaging (2D-Cohort). Vascular variations were evaluated by ascertaining the presence of renal arteries > 1, prehilar branching arteries, and arteries anterior to veins. The proposed scoring system, termed RAL, encompassed three critical components: (R)adius (maximal tumor diameter in cm), (A)rtery (occurrence of arterial variations), and (L)ocation relative to the polar line. Comparison of the RAL scoring system was made with established nephrometry scoring systems.</div></div><div><h3>Results</h3><div>A total of 48 (60%) patients exhibited at least one vascular variation. In the 2D-Cohort, patients with vascular variations experienced significantly prolonged operation time, increased bleeding volume, and extended warm ischemia time compared with those without vascular variations. Conversely, the presence of vascular variations did not significantly affect operative parameters in the 3D-Cohort. Furthermore, the 2D-Cohort demonstrated a notable decline in both short- and long-term estimated glomerular filtration rate (eGFR) changes compared with the 3D-Cohort, a trend consistent across patients with warm ischemia time ≥ 25 min and those with vascular variations. Notably, the 2D-Cohort exhibited a larger margin of normal renal tissue compared with the 3D-Cohort. Elevated RAL scores correlated with larger tumor size, prolonged operation time, extended warm ischemia time, and substantial postoperative eGFR decrease. The RAL scoring system displayed superior predictive capabilities in assessing postoperative eGFR changes compared with conventional nephrometry scoring systems.</div></div><div><h3>Conclusions</h3><div>Our proposed 3D vascular variation-based nephrometry scoring system offers heightened proficiency in preoperative assessment, precise prediction of surgical complexity, and more accurate evaluation of postoperative renal function in CERT patients.</div></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"4 4","pages":"Pages 346-353"},"PeriodicalIF":7.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11674429/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142904370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01DOI: 10.1016/j.jncc.2024.04.001
Juan Zhu , Lingbin Du , Huizhang Li , Xianhui Ran , Hongmei Zeng , Wenqiang Wei
Background
Esophageal cancer (EC) remains a global health challenge due to its poor prognosis. China and the United States of America (USA) represent two distinct epicenters of EC burden. Understanding the EC disparities in these two countries is vital for tailoring prevention strategies, optimizing treatment, and enhancing outcomes in both countries. Yet, there lacks a comprehensive comparison of EC characteristics between the two countries.
Methods
In this multicenter, retrospective hospital-based study, we enrolled primary EC patients who received their initial treatment at one of 23 hospitals in China during 2016–2017. Using electronic medical records and cancer registration records, information on demographics, lifestyle, and clinicopathological characteristics (including tumor site, pathology, stage, metastases, differentiation, and treatment) were collected. Additionally, we compared these data with the clinicopathological information of invasive EC patients diagnosed in 2016–2017 from the Surveillance, Epidemiology, and End Results (SEER) database in the USA.
Results
A total of 6,658 EC patients in China and 8,555 EC patients in the USA were included finally. 85.5% (n = 5,694) of EC were esophageal squamous cell carcinoma (ESCC) in China, while esophageal adenocarcinoma (EAC) was prominent in the USA (58.9%, n = 5,041). Among EC patients with known staging, the proportion of early stage was higher in China compared to the USA (48.3% vs. 30.5%). Among ESCC patients, early-stage cases were higher in China than in the USA (49.8% vs. 31.8%), while among EAC patients, late-stage cases were higher in China than in the USA (77.3% vs. 68.5%) (all P < 0.001). In China, EC mainly occurred in the middle third (60.2%) of the esophagus, whereas in the USA, it was more common in the lower third (59.9%) of the organ. Compared with EC patients with known metastatic status in the USA, China had fewer cases of lymph node metastases (51.4% vs. 57.7%) and distant metastases (7.9% vs. 33.8%). Regarding treatment, China had more surgical therapy (53.7% vs. 22.6%), less radiotherapy (35.6% vs. 53.3%), and less chemotherapy (46.7% vs. 59.7%) compared to the USA.
Conclusions
This study reveals notable disparities in EC between China and the USA, encompassing epidemiological, clinicopathological, and treatment dimensions. These findings provide insight for tailored strategies addressing regional variations in clinicopathological and therapeutic characteristics.
背景：食管癌（EC）由于预后不良仍然是一个全球性的健康挑战。中国和美利坚合众国（美国）是欧共体负担的两个不同中心。了解这两个国家的EC差异对于调整预防战略、优化治疗和提高两国的结果至关重要。然而，两国之间缺乏对电子商务特征的全面比较。方法：在这项以医院为基础的多中心回顾性研究中，我们招募了2016-2017年在中国23家医院之一接受初始治疗的原发性EC患者。使用电子医疗记录和癌症登记记录，收集了人口统计学、生活方式和临床病理特征（包括肿瘤部位、病理、分期、转移、分化和治疗）的信息。此外，我们将这些数据与美国监测、流行病学和最终结果（SEER）数据库中2016-2017年诊断的侵袭性EC患者的临床病理信息进行了比较。结果：中国共纳入6658例EC患者，美国共纳入8555例EC患者。在中国，85.5% （n = 5,694）的EC为食管鳞状细胞癌（ESCC），而在美国，食管腺癌（EAC）占58.9% （n = 5,041）。在已知分期的EC患者中，中国早期的比例高于美国（48.3%对30.5%）。在ESCC患者中，中国的早期病例高于美国（49.8%比31.8%），而在EAC患者中，中国的晚期病例高于美国（77.3%比68.5%）（均P < 0.001）。在中国，EC主要发生在食管的中间三分之一（60.2%），而在美国，EC更常见于该器官的下三分之一（59.9%）。与美国已知转移状态的EC患者相比，中国的淋巴结转移病例（51.4% vs. 57.7%）和远处转移病例（7.9% vs. 33.8%）较少。在治疗方面，与美国相比，中国手术治疗较多（53.7%对22.6%），放疗较少（35.6%对53.3%），化疗较少（46.7%对59.7%）。结论：本研究揭示了中国和美国在EC方面的显著差异，包括流行病学、临床病理和治疗方面。这些发现为解决临床病理和治疗特征的区域差异提供了量身定制的策略。
{"title":"Clinicopathological and therapeutic comparisons of esophageal cancer between China and the USA: a multicenter hospital-based study","authors":"Juan Zhu , Lingbin Du , Huizhang Li , Xianhui Ran , Hongmei Zeng , Wenqiang Wei","doi":"10.1016/j.jncc.2024.04.001","DOIUrl":"10.1016/j.jncc.2024.04.001","url":null,"abstract":"<div><h3>Background</h3><div>Esophageal cancer (EC) remains a global health challenge due to its poor prognosis. China and the United States of America (USA) represent two distinct epicenters of EC burden. Understanding the EC disparities in these two countries is vital for tailoring prevention strategies, optimizing treatment, and enhancing outcomes in both countries. Yet, there lacks a comprehensive comparison of EC characteristics between the two countries.</div></div><div><h3>Methods</h3><div>In this multicenter, retrospective hospital-based study, we enrolled primary EC patients who received their initial treatment at one of 23 hospitals in China during 2016–2017. Using electronic medical records and cancer registration records, information on demographics, lifestyle, and clinicopathological characteristics (including tumor site, pathology, stage, metastases, differentiation, and treatment) were collected. Additionally, we compared these data with the clinicopathological information of invasive EC patients diagnosed in 2016–2017 from the Surveillance, Epidemiology, and End Results (SEER) database in the USA.</div></div><div><h3>Results</h3><div>A total of 6,658 EC patients in China and 8,555 EC patients in the USA were included finally. 85.5% (<em>n</em> = 5,694) of EC were esophageal squamous cell carcinoma (ESCC) in China, while esophageal adenocarcinoma (EAC) was prominent in the USA (58.9%, <em>n</em> = 5,041). Among EC patients with known staging, the proportion of early stage was higher in China compared to the USA (48.3% vs. 30.5%). Among ESCC patients, early-stage cases were higher in China than in the USA (49.8% vs. 31.8%), while among EAC patients, late-stage cases were higher in China than in the USA (77.3% vs. 68.5%) (all <em>P</em> < 0.001). In China, EC mainly occurred in the middle third (60.2%) of the esophagus, whereas in the USA, it was more common in the lower third (59.9%) of the organ. Compared with EC patients with known metastatic status in the USA, China had fewer cases of lymph node metastases (51.4% vs. 57.7%) and distant metastases (7.9% vs. 33.8%). Regarding treatment, China had more surgical therapy (53.7% vs. 22.6%), less radiotherapy (35.6% vs. 53.3%), and less chemotherapy (46.7% vs. 59.7%) compared to the USA.</div></div><div><h3>Conclusions</h3><div>This study reveals notable disparities in EC between China and the USA, encompassing epidemiological, clinicopathological, and treatment dimensions. These findings provide insight for tailored strategies addressing regional variations in clinicopathological and therapeutic characteristics.</div></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"4 4","pages":"Pages 318-325"},"PeriodicalIF":7.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11674431/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142904359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01DOI: 10.1016/j.jncc.2024.07.003
Ying Wang , Jingying Nong , Baohua Lu , Yuan Gao , Mingming Hu , Cen Chen , Lina Zhang , Jinjing Tan , Xiaomei Yang , Peter Ping Lin , Xingsheng Hu , Tongmei Zhang
Background
Small cell lung cancer (SCLC) is a highly aggressive disease characterized by early metastasis. Aneuploid CD31- disseminated tumor cells (DTCs) and CD31+ disseminated tumor endothelial cells (DTECs) residing in the bone marrow are generally considered as the initiators of metastatic process. However, the clinical significance of DTCs and DTECs in SCLC remains poorly understood. The aim of this study is to investigate the clinical implications of diverse subtypes of highly heterogeneous DTCs and DTECs in SCLC patients.
Methods
Subtraction enrichment and immunostaining-fluorescence in situ hybridization (SE-iFISH) was applied to enrich and perform comprehensive morphologic, karyotypic, and phenotypic characterization of aneuploid DTCs and DTECs in 30 patients. Additionally, co-detection of circulating tumor cells (CTCs) and circulating tumor endothelial cells (CTECs) was conducted on 24 of the enrolled patients. Proof-of-concept of the whole exon sequencings (WES) on precisely selected different subtypes of CTCs or DTCs, longitudinally detected from a representative case with pathologically confirmed bone marrow metastasis, was validated to feasibly reveal genetic mutations in these cells.
Results
DTCs, DTECs and their subtypes were readily detectable in SCLC patients. Comparative analysis revealed that the number of DTCs and DTECs was significantly higher than that of their corresponding CTCs and CTECs (P < 0.001 for both). Positive detection of disseminated tumor microemboli (DTM) or disseminated tumor endothelial microemboli (DTEM) was associated with inferior survival outcomes (P = 0.046 and P = 0.048). Patients with EpCAM+ DTCs detectable displayed significantly lower disease control rate (DCR) (16.67% vs 73.33%, P = 0.019), reduced median progression-free survival (mPFS) and median overall survival (mOS) compared with those with EpCAM- DTCs (P = 0.028 and P = 0.002, respectively). WES analysis indicated that post-treatment DTCs isolated from bone marrow at the time of disease progression shared more homologous somatic gene mutations with pre-treatment CTCs compared with post-treatment CTCs.
Conclusions
Our findings suggest that bone marrow sampling and characterization of DTC subtypes provided a valuable tool for predicting treatment response and the prognosis in SCLC. Moreover, DTCs inherit a greater amount of homologous somatic information from pre-treatment CTCs, indicating their potential role in disease progression and treatment resistance.
背景：小细胞肺癌（SCLC）是一种以早期转移为特征的高侵袭性疾病。非整倍体CD31-弥散性肿瘤细胞（dtc）和CD31+弥散性肿瘤内皮细胞（DTECs）通常被认为是转移过程的启动器。然而，dtc和dtec在SCLC中的临床意义仍然知之甚少。本研究的目的是探讨不同亚型的高度异质性dtc和dtec在SCLC患者中的临床意义。方法：采用减法富集和免疫染色-荧光原位杂交（se - fish）技术对30例患者的非整倍体dtc和dtec进行富集并进行全面的形态学、核型和表型表征。此外，对24例入组患者进行循环肿瘤细胞（ctc）和循环肿瘤内皮细胞（CTECs）的联合检测。对精确选择的ctc或dtc不同亚型的全外显子测序（WES）的概念验证，从病理证实的骨髓转移的代表性病例纵向检测，验证了可行地揭示这些细胞中的基因突变。结果：dtc、dtec及其亚型在SCLC患者中均可检测到。对比分析显示，dtc和dtec的数量明显高于相应的ctc和ctec的数量（P < 0.001）。弥散性肿瘤微栓塞（DTM）或弥散性肿瘤内皮微栓塞（DTEM）阳性检测与较差的生存结果相关（P = 0.046和P = 0.048）。与EpCAM- dtc患者相比，检测到EpCAM+ dtc患者的疾病控制率（DCR）显著降低（16.67% vs 73.33%, P = 0.019），中位无进展生存期（mPFS）和中位总生存期（mOS）降低（P = 0.028和P = 0.002）。WES分析表明，在疾病进展时从骨髓中分离的治疗后的dtc与治疗前的ctc相比，具有更多的同源体细胞基因突变。结论：我们的研究结果表明，骨髓取样和DTC亚型的表征为预测SCLC的治疗反应和预后提供了有价值的工具。此外，dtc从治疗前的ctc继承了更多的同源体细胞信息，这表明它们在疾病进展和治疗抗性中发挥了潜在作用。
{"title":"Disseminated tumor cells in bone marrow as predictive classifiers for small cell lung cancer patients","authors":"Ying Wang , Jingying Nong , Baohua Lu , Yuan Gao , Mingming Hu , Cen Chen , Lina Zhang , Jinjing Tan , Xiaomei Yang , Peter Ping Lin , Xingsheng Hu , Tongmei Zhang","doi":"10.1016/j.jncc.2024.07.003","DOIUrl":"10.1016/j.jncc.2024.07.003","url":null,"abstract":"<div><h3>Background</h3><div>Small cell lung cancer (SCLC) is a highly aggressive disease characterized by early metastasis. Aneuploid CD31<sup>-</sup> disseminated tumor cells (DTCs) and CD31<sup>+</sup> disseminated tumor endothelial cells (DTECs) residing in the bone marrow are generally considered as the initiators of metastatic process. However, the clinical significance of DTCs and DTECs in SCLC remains poorly understood. The aim of this study is to investigate the clinical implications of diverse subtypes of highly heterogeneous DTCs and DTECs in SCLC patients.</div></div><div><h3>Methods</h3><div>Subtraction enrichment and immunostaining-fluorescence in situ hybridization (SE-iFISH) was applied to enrich and perform comprehensive morphologic, karyotypic, and phenotypic characterization of aneuploid DTCs and DTECs in 30 patients. Additionally, co-detection of circulating tumor cells (CTCs) and circulating tumor endothelial cells (CTECs) was conducted on 24 of the enrolled patients. Proof-of-concept of the whole exon sequencings (WES) on precisely selected different subtypes of CTCs or DTCs, longitudinally detected from a representative case with pathologically confirmed bone marrow metastasis, was validated to feasibly reveal genetic mutations in these cells.</div></div><div><h3>Results</h3><div>DTCs, DTECs and their subtypes were readily detectable in SCLC patients. Comparative analysis revealed that the number of DTCs and DTECs was significantly higher than that of their corresponding CTCs and CTECs (<em>P</em> < 0.001 for both). Positive detection of disseminated tumor microemboli (DTM) or disseminated tumor endothelial microemboli (DTEM) was associated with inferior survival outcomes (<em>P</em> = 0.046 and <em>P</em> = 0.048). Patients with EpCAM<sup>+</sup> DTCs detectable displayed significantly lower disease control rate (DCR) (16.67% vs 73.33%, <em>P</em> = 0.019), reduced median progression-free survival (mPFS) and median overall survival (mOS) compared with those with EpCAM<sup>-</sup> DTCs (<em>P</em> = 0.028 and <em>P</em> = 0.002, respectively). WES analysis indicated that post-treatment DTCs isolated from bone marrow at the time of disease progression shared more homologous somatic gene mutations with pre-treatment CTCs compared with post-treatment CTCs.</div></div><div><h3>Conclusions</h3><div>Our findings suggest that bone marrow sampling and characterization of DTC subtypes provided a valuable tool for predicting treatment response and the prognosis in SCLC. Moreover, DTCs inherit a greater amount of homologous somatic information from pre-treatment CTCs, indicating their potential role in disease progression and treatment resistance.</div></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"4 4","pages":"Pages 335-345"},"PeriodicalIF":7.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11674436/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142904374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01DOI: 10.1016/j.jncc.2024.08.001
Xun Tian , Danhui Weng , Ye Chen , Yi Wang , Xiao Li , Xin Wang , Chen Cao , Danni Gong , Zhen Zeng , Qiongyan Wu , Xueqian Wang , Peng Wu , Lu Fan , Qinghua Zhang , Hui Wang , Zheng Hu , Xiaodong Cheng , Ding Ma
Objective
We investigated the relation between man papillomavirus (HPV) integration status and the immediate risk of cervical intraepithelial neoplasia (CIN), as well as the triage strategy based on HPV integration test.
Methods
4086 women aged 20 to 65 years in China were enrolled in 2015 for a prospective, population-based, clinical observational study to evaluate the triage performance of HPV integration. Cervical exfoliated cells were collected for HPV testing and cytologic test. If high-risk HPV was positive, HPV integration test was performed at baseline, 2-year and 5-year follow-up.
Results
At baseline, HPV integration was positively correlated with the severity of cervical pathology, ranging from 5.0% (15/301) in normal diagnosis, 6.9% (4/58) in CIN1, 31.0% (9/29) in CIN2, 70% (14/20) in CIN3, and 100% (2/2) in cervical cancer (P < 0.001). Compared with cytology, HPV integration exhibits comparable sensitivity and negative predictive value for the diagnosis of CIN3+, higher specificity (92.8% [90.2%–95.4%] vs. 75.5% [71.2%–79.8%], P < 0.001) and higher positive predictive value (36.4% [22.1%–50.6%] vs. 15.2% [8.5%–21.8%], P < 0.001). HPV integration testing strategy yielded a significantly lower colposcopy referral rate than cytology strategy (10.7% [44/410] vs. 27.3% [112/410], P < 0.001). The HPV integration-negative group exhibited the lowest immediate risk for CIN3+ (1.6%) and accounted for the largest proportion of the total population (89.3%), when compared with the normal cytology group (risk, 1.7%; proportion, 72.7%).
Conclusion
As a key molecular basis for the development of cervical cancer, HPV integration might be a promising triage strategy for HPV-positive patients.
研究目的我们研究了人乳头瘤病毒（HPV）整合状态与宫颈上皮内瘤变（CIN）即刻风险之间的关系，以及基于HPV整合检测的分诊策略。方法：2015年，我们在中国招募了4086名20至65岁的女性，开展了一项前瞻性、基于人群的临床观察研究，以评估HPV整合的分诊效果。采集宫颈脱落细胞进行HPV检测和细胞学检测。如果高危HPV阳性，则在基线、2年和5年随访时进行HPV整合测试：基线时，HPV整合与宫颈病变的严重程度呈正相关，正常诊断为5.0%（15/301），CIN1为6.9%（4/58），CIN2为31.0%（9/29），CIN3为70%（14/20），宫颈癌为100%（2/2）（P < 0.001）。与细胞学相比，HPV 整合检测对 CIN3+ 诊断的灵敏度和阴性预测值相当，特异性更高（92.8% [90.2%-95.4%] vs. 75.5% [71.2%-79.8%]，P < 0.001），阳性预测值更高（36.4% [22.1%-50.6%] vs. 15.2% [8.5%-21.8%]，P < 0.001）。HPV整合检测策略的阴道镜检查转诊率明显低于细胞学策略（10.7% [44/410] vs. 27.3% [112/410]，P < 0.001）。与细胞学正常组（风险，1.7%；比例，72.7%）相比，HPV 整合阴性组的 CIN3+ 直接风险最低（1.6%），占总人数的比例最大（89.3%）：作为宫颈癌发病的关键分子基础，HPV整合可能是对HPV阳性患者进行分诊的一种有前途的策略。
{"title":"Risk assessment and triage strategy of cervical cancer primary screening on HPV integration status: 5-year follow-up of a prospective cohort study","authors":"Xun Tian , Danhui Weng , Ye Chen , Yi Wang , Xiao Li , Xin Wang , Chen Cao , Danni Gong , Zhen Zeng , Qiongyan Wu , Xueqian Wang , Peng Wu , Lu Fan , Qinghua Zhang , Hui Wang , Zheng Hu , Xiaodong Cheng , Ding Ma","doi":"10.1016/j.jncc.2024.08.001","DOIUrl":"10.1016/j.jncc.2024.08.001","url":null,"abstract":"<div><h3>Objective</h3><div>We investigated the relation between man papillomavirus (HPV) integration status and the immediate risk of cervical intraepithelial neoplasia (CIN), as well as the triage strategy based on HPV integration test.</div></div><div><h3>Methods</h3><div>4086 women aged 20 to 65 years in China were enrolled in 2015 for a prospective, population-based, clinical observational study to evaluate the triage performance of HPV integration. Cervical exfoliated cells were collected for HPV testing and cytologic test. If high-risk HPV was positive, HPV integration test was performed at baseline, 2-year and 5-year follow-up.</div></div><div><h3>Results</h3><div>At baseline, HPV integration was positively correlated with the severity of cervical pathology, ranging from 5.0% (15/301) in normal diagnosis, 6.9% (4/58) in CIN1, 31.0% (9/29) in CIN2, 70% (14/20) in CIN3, and 100% (2/2) in cervical cancer (<em>P</em> < 0.001). Compared with cytology, HPV integration exhibits comparable sensitivity and negative predictive value for the diagnosis of CIN3+, higher specificity (92.8% [90.2%–95.4%] vs. 75.5% [71.2%–79.8%], <em>P</em> < 0.001) and higher positive predictive value (36.4% [22.1%–50.6%] vs. 15.2% [8.5%–21.8%], <em>P</em> < 0.001). HPV integration testing strategy yielded a significantly lower colposcopy referral rate than cytology strategy (10.7% [44/410] vs. 27.3% [112/410], <em>P</em> < 0.001). The HPV integration-negative group exhibited the lowest immediate risk for CIN3+ (1.6%) and accounted for the largest proportion of the total population (89.3%), when compared with the normal cytology group (risk, 1.7%; proportion, 72.7%).</div></div><div><h3>Conclusion</h3><div>As a key molecular basis for the development of cervical cancer, HPV integration might be a promising triage strategy for HPV-positive patients.</div></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"4 4","pages":"Pages 311-317"},"PeriodicalIF":7.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11674434/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142904141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The burden of breast cancer in women of different menopausal status has not been assessed in China previously. We aim to evaluate and project the burden of breast cancer in different menopausal status in China.
Methods
The incidence and mortality of breast cancer were estimated using the data of 554 cancer registries in 2017 and the trends of incidence and mortality of 112 cancer registries from 2010 to 2017. Data from 22 continued cancer registries from 2000 to 2017 were applied for long-term trend projection to 2030 using the Bayesian age-period-cohort model. Menopausal status was stratified by age, with premenopause defined as chronological age <45 years, perimenopause defined as 45–54 years, and postmenopause defined as ≥55 years.
Results
Approximately 352,300 incident cases and 74,200 deaths of breast cancer occurred in China in 2020, contributing to 2.6 million disability-adjusted life years (DALYs). Perimenopausal women had the highest incidence, prevalence, and DALYs rates, with the rates being 100.3 per 100,000, 819.2 per 100,000 and 723.1 per 100,000 persons. While postmenopausal women had the highest mortality rates (25.5 per 100,000 persons). From 2000 to 2017, the largest increase in incidence and mortality for breast cancer was observed in postmenopausal women with an average annual percentage change (AAPC) of 5.6% and 2.94%. The number of breast cancer cases and deaths will increase to 452,000 and 98,800 in 2030, resulting in 3.2 million DALYs.
Conclusions
The burden of breast cancer is rapidly increasing in China and varies among different menopausal status. Specific prevention and control strategies for women in different menopausal status will be more helpful in reducing the rapidly growing trends of breast cancer.
{"title":"The burden and long-term trends of breast cancer by different menopausal status in China","authors":"Shaoyuan Lei , Rongshou Zheng , Siwei Zhang , Wenqiang Wei","doi":"10.1016/j.jncc.2024.04.007","DOIUrl":"10.1016/j.jncc.2024.04.007","url":null,"abstract":"<div><h3>Background</h3><div>The burden of breast cancer in women of different menopausal status has not been assessed in China previously. We aim to evaluate and project the burden of breast cancer in different menopausal status in China.</div></div><div><h3>Methods</h3><div>The incidence and mortality of breast cancer were estimated using the data of 554 cancer registries in 2017 and the trends of incidence and mortality of 112 cancer registries from 2010 to 2017. Data from 22 continued cancer registries from 2000 to 2017 were applied for long-term trend projection to 2030 using the Bayesian age-period-cohort model. Menopausal status was stratified by age, with premenopause defined as chronological age <45 years, perimenopause defined as 45–54 years, and postmenopause defined as ≥55 years.</div></div><div><h3>Results</h3><div>Approximately 352,300 incident cases and 74,200 deaths of breast cancer occurred in China in 2020, contributing to 2.6 million disability-adjusted life years (DALYs). Perimenopausal women had the highest incidence, prevalence, and DALYs rates, with the rates being 100.3 per 100,000, 819.2 per 100,000 and 723.1 per 100,000 persons. While postmenopausal women had the highest mortality rates (25.5 per 100,000 persons). From 2000 to 2017, the largest increase in incidence and mortality for breast cancer was observed in postmenopausal women with an average annual percentage change (AAPC) of 5.6% and 2.94%. The number of breast cancer cases and deaths will increase to 452,000 and 98,800 in 2030, resulting in 3.2 million DALYs.</div></div><div><h3>Conclusions</h3><div>The burden of breast cancer is rapidly increasing in China and varies among different menopausal status. Specific prevention and control strategies for women in different menopausal status will be more helpful in reducing the rapidly growing trends of breast cancer.</div></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"4 4","pages":"Pages 326-334"},"PeriodicalIF":7.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141694703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01DOI: 10.1016/j.jncc.2024.06.004
Yi Dong , Liaqat Khan , Yi Yao
Immune checkpoint inhibitors (ICIs) have significantly improved outcomes for patients with advanced driver-negative non-small cell lung cancer (NSCLC). However, targeted therapy remains the preferred treatment for advanced driver-positive NSCLC, including cases with epidermal growth factor receptor (EGFR) mutations. Considering the variability in EGFR-mutant NSCLC, including expression levels of programmed cell death ligand 1 (PD-L1), tumor mutation burden (TMB), and other immunological features, the application of immunotherapy in this group is still a subject of investigation. Therefore, we have summarized and analyzed the immunological characteristics and regulatory mechanisms of different EGFR mutations in NSCLC, as well as the current clinical application of immunotherapy in the EGFR-mutant population, to provide a reference for future research.
{"title":"Immunological features of EGFR-mutant non-small cell lung cancer and clinical practice: a narrative review","authors":"Yi Dong , Liaqat Khan , Yi Yao","doi":"10.1016/j.jncc.2024.06.004","DOIUrl":"10.1016/j.jncc.2024.06.004","url":null,"abstract":"<div><div>Immune checkpoint inhibitors (ICIs) have significantly improved outcomes for patients with advanced driver-negative non-small cell lung cancer (NSCLC). However, targeted therapy remains the preferred treatment for advanced driver-positive NSCLC, including cases with epidermal growth factor receptor (EGFR) mutations. Considering the variability in EGFR-mutant NSCLC, including expression levels of programmed cell death ligand 1 (PD-L1), tumor mutation burden (TMB), and other immunological features, the application of immunotherapy in this group is still a subject of investigation. Therefore, we have summarized and analyzed the immunological characteristics and regulatory mechanisms of different EGFR mutations in NSCLC, as well as the current clinical application of immunotherapy in the EGFR-mutant population, to provide a reference for future research.</div></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"4 4","pages":"Pages 289-298"},"PeriodicalIF":7.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11674437/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142904377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号